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Abstract
Antibiotic resistance in Helicobacter pylori is a factor preventing its successful eradication.
Particularly in developing countries, resistance against commonly used antibiotics is wide-
spread. Here, we present an epidemiological study from Nigeria with 111 isolates. We ana-
lyzed the associated disease outcome, and performed a detailed characterization of these
isolated strains with respect to their antibiotic susceptibility and their virulence characteris-
tics. Furthermore, statistical analysis was performed on microbiological data as well as
patient information and the results of the gastroenterological examination. We found that the
variability concerning the production of virulence factors between strains was minimal, with
96.4% of isolates being CagA-positive and 92.8% producing detectable VacA levels. In
addition, high frequency of bacterial resistance was observed for metronidazole (99.1%),
followed by amoxicillin (33.3%), clarithromycin (14.4%) and tetracycline (4.5%). In conclu-
sion, this study indicated that the infection rate of H. pylori infection within the cohort in the
present study was surprisingly low (36.6%). Furthermore, an average gastric pathology was
observed by histological grading and bacterial isolates showed a uniform pathogenicity pro-
file while indicating divergent antibiotic resistance rates.
2 Introduction
Helicobacter pylori (H. pylori) is a microaerophilic, highly motile, Gram-negative bacterium,
which resides in the human gastric mucus layer. H. pylori contains and produces multiple
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virulence factors, including the cytotoxin-associated gene A (cagA) and the vacuolating cyto-
toxin (vacA), both of which are associated with a marked increase in the risk of disease devel-
opment [1]. The 37 kb cag-pathogenicity island (cag-PAI) encodes cagA, as well as the cag
Type IV Secretion System (cag-T4SS), which can form a membrane-spanning secretion chan-
nel and an extracellular pilus. Via contact with the target-cell receptor α5β1 integrin heterodi-
mer [2], the T4SS translocates the effector protein CagA into host cells [3] and causes secretion
of the proinflammatory chemokine interleukin-8 (IL-8) from gastric epithelial cells [4].
Injected CagA is tyrosine-phosphorylated on a number of Glu-Pro-Ile-Tyr-Ala (EPIYA)
motifs within the C-terminal region of CagA protein, allowing it to interact with several cellu-
lar protein partners [5]. Due to these downstream effects and the correlation with cancer,
CagA is considered to be a bacterial oncoprotein [6]. VacA, a pore-forming toxin, induces vac-
uoles in gastric epithelial cells [7], but has a number of other effects, such as inhibition of pro-
liferation and IL-2 secretion by T cells [8] and induction of apoptosis in gastric epithelial cells
[9].
Infection with H. pylori is a major cause of gastroduodenal disease, including chronic and
active gastritis, peptic ulcer disease, MALT lymphoma and gastric carcinoma [10]. The preva-
lence within the human population is highly variable, ranging from approximately 20% of the
population within industrial countries and approaching 80% in developing countries [11]. In
developing countries such as Nigeria antibiotic resistance rates can reach up to 100%, a major
reason for eradication failure. There is so far a lack of epidemiological and all-encompassing
studies in Nigeria, with only five publications concerning the status of antibiotic resistance in
Nigeria published in 1999, 2001, 2007, 2009 and 2013 [12–16]. In these studies between 31 and
186 patients were analyzed, and antibiotic resistance of H. pylori was determined to be as fol-
lows: amoxicillin (0% - 100%), clarithromycin (12.7% - 100%), metronidazole (40% - 100%),
and tetracycline (11% - 100%). Thus, our knowledge about the current state of drug resistance
is low and, due to small sample sizes, the data show wide variation. To better understand the
status and consequences of H. pylori infections in Nigeria, we studied the antibiotic resistance
of isolated strains and attempted to correlate this to patient data, demographic patterns, dis-
ease outcome and characteristics of the isolated strains.
To accomplish this, we established a network of eight hospitals in Nigeria, with coordina-
tion centers located in Lagos [17] and Munich (Germany). To study the epidemiological situa-
tion, this network was used to collect biopsies, patient-isolated strains, patient questionnaires
and the according diagnosis of the gastroenterologist, which was finally statistically correlated.
This provided a very detailed characterization of the isolates, which included investigation of
antibiotic resistance, and placed it in context with the patient information. From this work,
involving 577 patients, a clearer overview of the current situation of H. pylori infections in
Nigeria was obtained.
3 Methods
3.1 Study design
577 patients were recruited between August 2010 and December 2013 in eight different hospi-
tals in Nigeria. Five hospitals were located in Lagos, one in Ibadan, one in Ile-Ife and one in
Jos. A questionnaire, a form with gastroenterological results and a signed consent were filled
out by and with each patient, respectively. Furthermore an urease breath test (UBT), the gold
standard in H. pylori diagnostics, was performed, and six biopsies (three from the antrum and
three from the corpus) were taken from each patient. One biopsy from the antrum was used to
confirm the H. pylori infection by a campylobacter-like organism (CLO) test, one antrum and
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one corpus biopsy were used for isolation of the H. pylori strain responsible, while the other
three biopsies were used for histological analysis.
Inclusion criteria were the treatment in one of the eight mentioned hospitals, the agreement
to participate this study, and being a patient showing both stomach afflictions and an expected
H. pylori infection. Furthermore, patients with prior antibiotic treatment were not excluded
(see discussion).
The recruitment, the gastroenterological examination, the UBT, the CLO test, the fixation
of the biopsies, the isolation of the strains, MIC test, polymerase chain reaction (PCR), western
blotting as well as the histological grading were performed in Nigeria (Fig 1). Throughout the
course of this study, 577 patient questionnaires, 571 forms with gastroenterological results, 351
fixed biopsies (from 136 patients) and 111 isolates (from 50 patients) were sent to Munich
(Germany). Due to the challenging field conditions in Nigeria, 111 isolates is the final number
and all following results refer to this number. In Munich, further characterization of the iso-
lates, the repetition of the MIC test, the western blotting, the PCR, the procedure of the enzyme
linked immunosorbent assay (ELISA), the confirmation of the histological grading as well as
the final statistical analysis were performed–thus determining any correlation between H.
pylori virulence, antibiotic resistance, patient information and disease outcome.
3.2 Urease breath test
The urease breath test (UBT) test was obtained from Tri-Med Distributors in Australia. Poten-
tially-infected patients fasted either overnight or for a minimum of four hours. A PYtest cap-
sule containing a known amount of 14C-labelled urea was provided to patients to drink with
30 ml of water, followed after 3 minutes by a further 30 ml of water. After further 7 min a
breath sample was collected in a sterilized mylar balloon. Following contact between 14C-
labelled urea and stomach-resident H. pylori, the molecule was hydrolyzed into 14C-carbon
dioxide and ammonia. The carbon dioxide then entered the bloodstream and was in turn
exhaled by the patient. The collection balloon containing patient breath samples was then ana-
lyzed either directly in the hospital or sent to a pathology laboratory for analysis. The contents
of the balloon were dissolved into breath collection fluid and then liquid scintillation fluid was
added to quantify the degree of 14C present. Scintillation values below 50 DPM (disintegrations
per minute) were considered to be negative, values over 200 DPM as positive and all values
between as “borderline”.
3.3 CLO test
The campylobacter-like organism (CLO) test was obtained from Tri-Med Distributors in Aus-
tralia. The test kit contains urea, and utilizes a pH-mediated color change from yellow to red
as a marker for the presence of H. pylori within the biopsy.
3.4 H. pylori isolation
The biopsy sample was rolled several times over a GC agar serum plate (Oxoid) containing
horse serum (80 ml/l), IsoVitaleXTM (10 ml/l; from BD, Germany), vancomycin (10 mg/l), tri-
methoprim (5mg/l), and nystatin (1 mg/l). Plates were then incubated for 5 to 9 days in a
microaerobic atmosphere (85% N2, 10% CO2, 5% O2) at 37˚C. Isolated bacteria were passaged
twice to obtain a vital and dense culture before storage at -80˚C. Since it is known that a patient
can harbor more than one strain, we have analyzed up to two colonies per antrum and corpus,
respectively.
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3.5 Transport of strains
For transport of the isolates from Lagos to Munich (Germany), strains were cultured on GC agar
serum plates (see above), passaged twice and transferred into Portagerm Pylori (bioMe´rieux SA
Mercy L’Etoile France) medium. In this state they were shipped to Munich (via DHL couriers).
3.6 PCR
PCR was performed in 25μl reaction mixtures, consisting of x1 PCR buffer, magnesium chlo-
ride (1.5 mM), dNTP (200 μM), primer (20 pmol) and 1U Taq DNA polymerase (Pan-bio-
tech). Amplification was carried out in a Peqlab Thermocycler using the following cycling
parameters: initial denaturation at 95˚C for 5 min, followed by 35 cycles of 95˚C for 30 sec,
54˚C for 30 sec and 72˚C according to amplicon length (1 min per 1000 bp). This was followed
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0176454.g001
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by a final extension of 72˚C for 10 min. The hpWAfrica strain J99 [18] and the hpEurope strain
P12 [19] were used as control strains. Primers are listed in Table 1.
3.7 Western blotting
Rabbit polyclonal antisera against CagA and VacA have been described previously [20].
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting
was performed as described [4], using polyvinylidene difluoride (PVDF) filters blocked with
5% non-fat milk powder in TBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl), 0.1% (v/v) Tween
20. Alkaline phosphatase-conjugated protein A or horseradish peroxidase-conjugated anti-
rabbit IgG antiserum was used to visualize bound antibody. The hspWAfrica strain J99 [18]
and the hpEurope strain P12 [19] were used as control strains.
3.8 Phosphorylation of translocated CagA
Standard infections of AGS cells with H. pylori strains and subsequent preparations for phos-
photyrosine immunoblotting were performed as described previously [3]. Briefly, cells were
infected with bacteria at a multiplicity of infection of 100 for 4 h at 37˚C, washed three times
and suspended in PBS containing 1mM EDTA, 1mM Na3VO4, 1mM PMSF, 10μg/ml leupep-
tin, and 10μg/ml pepstatin. Cells with adherent bacteria were collected by centrifugation and
resuspended in sample buffer. Tyrosine-phosphorylated proteins were analyzed by immuno-
blotting with the phosphotyrosine antiserum PY99 (Santa Cruz Biotechnologies). The hspWA-
frica strain J99 [18] and the hpEurope strain P12 [19] were used as control strains.
3.9 IL-8 secretion by ELISA
The production of IL-8 by AGS cells after infection with H. pylori strains for 4 h was deter-
mined from cell supernatants by a sandwich enzyme linked immunosorbent assay (ELISA),
as previously described [4]. The hpEurope strain P12 [19] was used as control strain.
Table 1. Primer sequences.
Target
gene
Sense primer Antisense primer Amplicon
length
16S rRNA AAGGCTATGACGGGTATCCG GGGGGTTGCGCTCGTTGCGGG 826 bp
23S rRNA CCACAGCGATGTGGTCTCAG GGGACCGAACTGTCTCACGACG 878 bp
cagA CCATCGATGGTAAAAATGTGAATCGT CAGGTACCGCGGCCGCTTAAGATTTTTGGAAACCAC 3700 bp
cagA ACCGCTCGAGAACCCTAGTCGGTAATGGG ATATCGATTTAAGCCAATTTTTGATTCCTTG 500 bp
dupA CTACAATATAGCTCTCAAAAG AGCAATAAAACGCTTAAAAGTCTC 2959 bp
dupA GCCAGAGATTTCAATGATGTC AAAAATTTAGGCTCAAAGTCTG 970 bp
vacA s1 CTGCTTGAATGCGCCAAAC ATGGAAATACAACAAACACAC 259 bp
vacA s2 CTGCTTGAATGCGCCAAAC ATGGAAATACAACAAACACAC 286 bp
vacA m1 GGTCAAAATGCGGTCATGG CCATTGGTACCTGTAGAAAC 290 bp
vacA m2 CATAACTAGCGCCTTGCAC CATAACTAGCGCCTTGCAC 352 bp
atpA GGACTAGCGTTAAACGCACG CTTGAAACCGACAAGCCCAC 841 bp
efp GGCAATTTGGATGAGCGAGCTC CTTCACCTTTTCAAGATACTC 559 bp
mutY GTGGTTGTAGYTGGAAACTTTACAC CTTAAGCGTGTGTYTTTCTAGG 676 bp
ppa GGAGATTGCAATGAATTTAGA GTGGGGTTAARATCGTTAAATTG 706 bp
HptrpC TAGAATGCAAAAAAGCATCGCCCTC TAAGCCCGCACACTTTATTTTCGCC 633 bp
ureI AGGTTATTCGTAAGGTGCG GTTTAAATCCCTTAGATTGCC 686 bp
yphC CACGCCTATTTTTTTGACTAAAAAC CATTYACCCTCCCAATGATGC 734 bp
https://doi.org/10.1371/journal.pone.0176454.t001
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3.10 MLST
For strain phylogeny, we used multilocus sequence typing analysis [21]. Partial nucleotide
sequences of the housekeeping genes atpA, efp, mutY, ppa, trpC, ureI and yphC were deter-
mined for each strain by sequencing the corresponding PCR products; primer pairs are listed
in Table 1. The resulting sequences were concatenated and aligned with the corresponding
sequences from 345 reference strains from the MLST database [21] and from 45 fully
sequenced genomes [22], using the Muscle algorithm within MEGA5.2 [23]. Phylogenetic
trees were constructed and tested by neighbor joining with MEGA5.2, using the Kimura
2-parameter model of nucleotide substitution, and 1,000 bootstrap replications.
3.11 MIC test
The minimal inhibitory concentration (MIC) test was obtained from Bestbion in Germany.
The strains were grown as a liquid culture in Brucella Broth + 10% fetal calf serum (FCS) over-
night until OD 1.0. 400 μl of the liquid culture was transferred to a GC agar serum plate (see
above), after which an appropriate antibiotic strip was placed on the plate. Antimicrobial agent
concentrations ranged from 0.016 to 256 μg/mL. After two days incubation the zone of inhibi-
tion was measured according to the manufacturer’s instructions under consideration of rec-
ommended MIC breakpoints (EUCAST Clinical Breakpoint Table v. 6.0, valid from 2016-01-
01): amoxicillin 0.125–0.125 μg/mL, clarithromycin 0.25–0.5 μg/mL, tetracycline 1–1 μg/mL,
metronidazole 8–8 μg/mL (range describes the value between sensitivity and resistance >).
The H. pylori strains P12 [19] and J99 [18] were used as control strains.
3.12 Transformation
PCR products of 23S rRNA of resistant isolates were generated and transformed in H. pylori
strain J99 by natural transformation, as described previously [24]. H. pylori transformants
were selected on serum agar plates containing 6 mg/l clarithromycin.
3.13 Histology
Hematoxylin and eosin stained longitudinal paraffin sections of antrum and corpus were on
the intensity of inflammation, metaplasia, and presence of gastric mucosa associated lymphoid
tissue (MALT), as well as the presence and occurrence of atrophies, metaplasia, dysplasia, can-
cer, erosion and ulcers. Grading was performed according to the updated Sydney System [25]
under blinded conditions by expert pathologists in Lagos (FBA) as well as in Munich (SM).
3.14 Ethics
The study was reviewed and approved by the Ethics Committee of the Nigerian Institute of
Medical Research (registration number IORG0002656) and of the Ludwig-Maximilians-Uni-
versity Munich (registration number 335–08). The study was conducted in line with the Decla-
ration of Helsinki and informed consent was obtained from all study participants.
3.15 Statistical methods
All variables were described using appropriate measures of location and dispersion, stratified
for gender. Interrelations between clinical, pathologic, and laboratory findings were investi-
gated bivariately using chi-squared tests for nominal and rank sum tests for ordinal or quanti-
tative outcomes. Due to the exploratory character of these analyses, all tests were performed on
a local alpha level of 5% without any correction for multiple testing. All analyses relied on the
Statistical Analysis System SAS, version 9.2 for Linux (SAS Institute, Cary, NC).
Helicobacter pylori in Nigeria
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4 Results
4.1 Low rate of H. pylori infection in Southern Nigeria
In order to prevent pre-selection of the cohort, inclusion criteria for the present study were
broad, comprising patients with both stomach afflictions and a possible or expected H. pylori
infection. The success of our criteria was supported by the demographic results (Table 2). The
gender of the participants was balanced, 54.9% of the participants were female and the major-
ity of patients were between 40 and 60 years old, suggesting that this group comprises a repre-
sentative cross-section.
In order to analyze the rate of H. pylori infection in the patient cohort, the results of the UBT
as well as the successful isolation of H. pylori were considered. Of 577 recruited patients 206
(35.7%) showed a positive result in the UBT. Interestingly, only 74.7% of the UBT positive
patients were confirmed in the CLO test (data not shown). Biopsy material from all 577 patients
was used for H. pylori culture, independent of the UBT result (positive, negative or borderline)
and a total number of 111 H. pylori isolates were successfully cultivated from 50 patients. Inter-
estingly, five H. pylori isolates were successfully obtained from four UBT-negative patients and
Table 2. Demographic data of participating patients.
all patients
(n = 577)
UBT-positive patients
(n = 206)
patients with
successfully isolated
strains
(n = 50)
infected patients:
UBT-positive and/or
isolated strain
(n = 211)
Sex
female 315 54.6% 118 57.3% 24 48.0% 121 57.3%
male 261 45.2% 88 42.7% 26 52.0% 90 42.7%
unknown 1 0.2% 0 0.0% 0 0.0% 211 0.0%
Age
0–10 1 0.2% 0 0.0% 0 0.0% 0 0.0%
11–20 12 2.1% 4 1.9% 2 4.0% 4 1.9%
21–30 60 10.4% 15 7.3% 4 8.0% 15 7.1%
31–40 94 16.3% 36 17.5% 7 14.0% 36 17.1%
41–50 125 21.7% 45 21.8% 13 26.0% 46 21.8%
51–60 130 22.5% 50 24.3% 13 26.0% 54 25.6%
61–70 93 16.1% 30 14.6% 4 8.0% 30 14.2%
71–80 32 5.5% 13 6.3% 2 4.0% 13 6.2%
81–90 8 1.4% 4 1.9% 1 2.0% 4 1.9%
91–100 1 0.2% 0 0.0% 0 0.0% 0 0.0%
101–110 2 0.3% 0 0.0% 0 0.0% 0 0.0%
unknown 19 3.3% 9 4.4% 4 8.0% 9 4.3%
UBT test
positive 206 35.7% 206 100.0% 45 90.0% 206 97.6%
negative 276 47.8% 0 0.0% 4 8.0% 4 1.9%
borderline 74 12.8% 0 0.0% 1 2.0% 1 0.5%
not recorded 21 3.6% 0 0.0% 0 0.0% 0 0.0%
City of examination
Lagos 327 56.7% 113 54.9% 39 78.0% 117 55.5%
Ife-Ife 104 18.0% 37 18.0% 6 12.0% 38 18.0%
Ibadan 61 10.6% 28 13.6% 2 4.0% 28 13.3.%
Jos 85 14.7% 28 13.6% 0 0.0% 28 13.3.%
https://doi.org/10.1371/journal.pone.0176454.t002
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one UBT-borderline patient. A patient was defined as infected when at least one positive result
was obtained from either UBT or H. pylori culture, providing a calculated infection rate of
36.6%. This is not an infection prevalence since healthy people were not included and thus, this
number does not reflect the infection rate within the average Nigerian population.
4.2 Divergence in antibiotic resistance rates of H. pylori
The current rate of antibiotic resistance in Nigeria has not been decisively determined, and as
high levels of drug resistance of H. pylori may play an important role in therapeutic failure, we
decided to analyze the antibiotic resistance of the isolated strains. This was accomplished via
MIC testing of all 111 isolates, which indicated a nearly complete bacterial resistance to metro-
nidazole (99.1%), but lower rates of resistance to amoxicillin (33.3%), clarithromycin (14.4%)
and tetracycline (4.5%) (Fig 2A). However, considering the antibiotic resistance rates sepa-
rately, this study has confirmed the extremely high resistance rate of H. pylori against metroni-
dazole in Nigeria–which is in contrast to resistance levels against tetracycline, which were
surprisingly low.
We next sequenced the mid region of 23S rRNA of those 16 isolates which had shown a
clarithromycin resistance in the MIC test to determine if this drug resistance was due to point
mutations reported previously. Of these potential mutations, our isolates contained A2143C (2
of 16), A2143G (1 of 16) and A2144G (2 of 16), as well as other point mutations, one of which
(C2196T) has been described before [26], but with an unclear role. To examine whether these
mutations are involved in clarithromycin resistance, we transformed the clarithromycin-sensi-
tive J99wt strain with 23S rRNA PCR amplification products of all 16 resistant Nigerian iso-
lates. PCR products from resistant strains with point mutations at positions 2143 or 2144
induced clarithromycin resistance in J99wt, whereas none of the PCR products from the 11
Fig 2. Characterization of H. pylori isolates. 111 isolated strains were characterized by the status of resistance, the analysis of the major virulence
factors as well as their IL-8 expression. A: The bacterial resistance to amoxicillin, clarithromycin, metronidazole and tetracycline is shown as
percentage. These results are based on MIC tests. B. Black: shows PCR results of the genes cagA and vacA. Grey: shows the Western blotting results
of the proteins CagA, translocation of CagA into AGS cells, and VacA. C. Induction of IL-8 secretion by AGS cells in relation to H. pylori P12. Each dot
illustrates one isolate. Black: isolates produce VacA, CagA, and are also able to translocate CagA. Green: isolates which produce neither VacA nor
CagA and show no CagA translocation. Red: isolates which do produce VacA, but not CagA. Blue: isolates which produce and translocate CagA, but do
not produce VacA. Purple: isolates which produce VacA and CagA, but are not able to translocate CagA.
https://doi.org/10.1371/journal.pone.0176454.g002
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resistant strains with other point mutations (including C2196T) induced resistance (data not
shown). Thus, these other point mutations are unlikely to be responsible for the observed clari-
thromycin resistance. In conclusion, it is more likely that these 11 isolates utilize other muta-
tions or a completely different mechanism of resistance encoded outside the 23S rRNA.
4.3 H. pylori-infected patients show an average pathology and an almost
uniform presence of the major bacterial virulence factors
To analyze the disease outcome and its relation to the characteristics of H. pylori isolates, histo-
logical grading of stomach biopsies was performed. A maximum of three biopsies was obtained
from each patient for histological grading (one from antrum and two from corpus); in total 351
biopsies from 136 patients were analyzed. Chronic and active inflammation was found in most
of the patients stomachs, with only 30.2% of patients demonstrating the presence of MALT
(lymphoid aggregates or lymph follicles). In 7.1% and 5.4% of the biopsies, atrophy or metapla-
sia could be observed, respectively, while erosion was discovered in only two cases. However,
neither dysplasia, nor ulcer or cancer could be observed in the histology (Table 3). A statistical
correlation was found between UBT-positive patients and active as well as chronic inflamma-
tion (according to histological evaluation). The inflammation in the patients was graded using a
score from 0 (no inflammation) to 3 (strong inflammation). From all UBT-positive patients an
average score of 1.5 was observed in active inflammation, and a score of 1.9 in chronic inflam-
mation. In comparison, UBT-negative patients exhibited a score of 0.7 in active inflammation
(p< 0.001) and a score of 1.4 in chronic inflammation (p< 0.001). These differences were sta-
tistically significant. All other potential correlations were not significant or not analyzable.
As compared to histological findings, the gastroenterological findings resulted in a more
serious disease outcome: 37.4% of the patients showed a normal mucosa, 32.7% erosions,
Table 3. Pathology analyzed by a histological grading (based on the updated Sydney System (22)) in HE stained slides.
stomach biopsies n = 351 (136 patients)
Chronic inflammation Metaplasia
0 12 (3.4%) none 332 (94.6%)
1 83 (23.6%) complete intestinale m. 12 (3.4%)
2 218 (62.1%) incomplete intestinale m. 3 (0.9%)
3 38 (10.8%) compl. & incomplete m. 4 (1.1%)
Active inflammation Dysplasia
0 64 (18.2%) no 351 (100.0%)
1 120 (34.2%) yes 0 (0.0%)
2 145 (41.3%)
3 22 (6.3%) Erosion
no 349 (99.4%)
MALT yes 2 (0.6%)
none 245 (69.8%)
lymphoid aggregates 59 (16.8%) Ulcer
lymphollicles 24 (6.8%) no 351 (100.0%)
lymphoid agg.
& lymphollicles
23 (6.6%) yes 0 (0.0%)
Cancer
Atrophy no 351 (100.0%)
none 326 (92.9%) yes 0 (0.0%)
focal 13 (3.7%)
diffuse 6 (1.7%)
moderate 6 (1.7%)
https://doi.org/10.1371/journal.pone.0176454.t003
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24.2% hyperemia, 15.5% ulcers and two patients revealed gastric cancer (data not shown); all
other endoscopic findings (oedematous, polyps > 1cm, mucosal atrophy, haemorrhages,
excrescence, hypoemia) were below 10.0% and in the order as listed. Due to multiple observa-
tions within the same patient, as well as some missing information, these percentages do not
add up to 100%. Thus, the disease outcome analyzed by histology is relatively mild, but regard-
ing the endoscopic findings the pathology is considered as average for an African country.
To determine a possible correlation between the presence of the major virulence factors
and disease outcome, we examined the expression status and the functional characteristics of
the cag-PAI and VacA of all 111 H. pylori isolates. The majority of isolates were cagA- (98.2%)
as well as vacA-positive (100%), and all vacA sequences showed the s1/m1 genotype. In vitro
infection experiments of AGS gastric epithelial cells were performed and showed that 105 of
the 107 CagA-positive isolates were able to translocate CagA, suggesting that these isolates
were also able to inject CagA in the stomach in vivo. Furthermore, more than half of the strains
(53.2%) induced higher IL-8 expression levels in AGS cells than a commonly used laboratory
strain (P12). The characterization of the virulence factors and induced IL-8 secretion levels
associated with these isolates are summarized in Fig 2C and 2D).
To obtain further information on virulence factor characteristics, the CagA EPIYA regions
of 14 representative strains were sequenced (Fig 3). This region consists of three different
EPIYA motifs (A, B, and C), and it has been postulated that increased numbers of EPIYA-C
motifs correlate with stronger pathology in the patient [27]. Nine of the 14 isolates sequenced
here contained an ABC motif arrangement, the other five harbored either an AC motif (three
cases), an ACC motif (one case) or an ABCC motif (one case). Conspicuously, a conserved
KDKGPE motif was found upstream of the EPIYA-A motif in nine out of 14 sequences, how-
ever no correlation with pathology could be observed.
4.4 Characterized H. pylori isolates cluster with strains of the hpAfrica1
population and have a characteristic deletion in the ICEHptfs4b plasticity
zone
We have previously shown that the integrating conjugative element ICEHptfs4b, a plasticity
zone which carries the duodenal ulcer promoting (dupA) gene and its associated T4SS that has
been implicated in the formation of duodenal ulcers, is incomplete in several H. pylori isolates
from Western Africa. In particular, one specific gap was observed when compared to non-
African strains [22].
Fig 3. EPIYA motifs. EPIYA region sequences of 14 isolates including reference strains (196A, 26695,
ATCC43526, and P12) are shown (red). 9 isolates show the KDKGPE motif (blue) in front of the EPIYA-A
motif [28].
https://doi.org/10.1371/journal.pone.0176454.g003
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Utilizing PCR analysis, we observed a truncated right region of ICEHptfs4b identical to the
one previously described in 64 out of 65 strains analyzed, indicating that these strains do not
carry a functional dupA T4SS (data not shown). This observation further suggests that most, if
not all, West African strains carry this type of deletion. However, since it was observed that the
chance of successfully isolating H. pylori was much higher from hospitals located close to
Lagos, where the strain-isolation laboratory was located, one possibility was that the analyzed
strains are simply very closely related. Thus, 78% of the 111 characterized strains originated in
Lagos. To exclude that a generally low variance of the examined H. pylori isolates was the rea-
son for the genotype similarities, an MLST analysis was performed. MLST sequence analysis
indicated that all sequenced strains were hpAfrica 1 (hspWAfrica) strains, which was reflected
by clustering of the Nigerian isolates together with the reference strains 908 [29], Gambia 94–
24 [30], and J99 [18] (Fig 4). This analysis also indicated that at least six patients were infected
with multiple strains of H. pylori, as isolates originating from the same patient did not cluster
within the phylogenetic tree (data not shown).
5 Discussion
The UBT is still considered to be the gold standard in diagnosing H. pylori infection, especially
in developing countries where it is an often used and non-invasive test [31]. But we showed
clearly that UBT-negative patients can also be infected with H. pylori, as we have successfully
isolated H. pylori from five patients without positive UBT results. Since the UBT is, in general,
a reliable method to diagnose the presence of H. pylori, the most likely cause of this is failure in
either the technical performance of the test, or the assistance of the patients. Regardless of the
reason, it remains one of the most appropriate methods as the alternatives are limited to: (i)
biopsies, possible only in a few hospitals in Nigeria; (ii) analyzing stool samples, which is still a
less reliable assay than the UBT [32]; or (iii) using the CLO test, which is less sensitive (as
shown in the present study). Furthermore, even if the option to perform a gastroscopy and to
isolate biopsies is given, it remains expensive and is not an option for every patient. Thus, the
UBT remains the most reliable way to diagnose H. pylori infections.
As previously mentioned, the state of antibiotic resistance in Nigeria has been poorly stud-
ied. In the current study we demonstrated that 99.1% of isolates were resistant to metronida-
zole, with a significantly lower resistance rate to amoxicillin and clarithromycin, and a very
low resistance rate to tetracycline. Reported rates of antibiotic resistance throughout Africa are
predominantly higher (except for metronidazole) [33], with published rates of amoxicillin
resistance between 46% and 83%, clarithromycin resistance between 28% and 45%, tetracy-
cline resistance between 58% and 84% and metronidazole resistance ranging from 48% to
72%. Thus, when compared to other African countries, the resistance rates against amoxicillin,
clarithromycin, and tetracycline are comparatively low in Nigeria, but for no other African
country a metronidazole resistance rate of almost 100% has been reported. This might be
explained by the widespread use of metronidazole in Nigeria. As metronidazole is effective not
only against various bacteria but also against protozoa, it is very commonly used; mainly for
the treatment of diarrheal diseases [34], gynecological infections [35] and menstrual symptoms
[36]. In addition, 27.2% of the patients stated that they are taking antibiotics during an acute
episode (mostly before seeing a medical doctor) and 20.1% indicated taking antibiotics regu-
larly. Through many indications as well as the over-the-counter availability of antibiotics in
Nigeria the intake of metronidazole as well as other antibiotics is uncontrolled and frequent,
which is in turn due to differences in health care systems when compared to other countries.
Officially a public health insurance system covers the primary health care of each Nigerian citi-
zen, however this system, founded in 1999, is still in the implementation phase [37]. Because
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of this the private expenditure on health (in 2012) as a percentage of total expenditure on
health was 68.9% in Nigeria, as compared to 23.7% for Germany in the same year. Further-
more, general government expenditure on health as a percentage of total government expendi-
ture was 6.7% in Nigeria, as compared to 19.1% in Germany [38]. The outcome of these
factors is that the majority of treatment costs need to be covered by the patients themselves,
which often results in pre-emptive self-treatment by the patients.
Fig 4. Phylogenetic tree of strains used in this study and representative strains from different populations.
All strains used in this study are represented by blue dots, cluster with the hpAfrica1 (hspWAfrica) strains 908,
Gambia 94–24, and J99. Strains from other populations are color-coded as indicated.
https://doi.org/10.1371/journal.pone.0176454.g004
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A study performed in Germany in 2013 reported that in untreated patients H. pylori isolates
showed a resistance rate of 36.2% to metronidazole and 20.9% to clarithromycin. By compari-
son, a significantly higher resistance was detected in pre-treated patients; resistance to metro-
nidazole reached 69.7% while resistance to clarithromycin reached 73.7% [39]. However, since
patients pre-treated with antibiotics were not excluded in the present study, and the percentage
of pre-treated patients could not be determined unequivocally, a conclusion as to the signifi-
cance of pre-treatments on antibiotic resistance could not be drawn.
Thus, the lack of detailed information about self-medication as well as the knowledge about
uncontrolled and frequented intake of antibiotics in Nigeria might be responsible for the high
resistance level of 99.1% against metronidazole.
The antibiotic resistance of patient isolates was analyzed by MIC test, furthermore the 23S
rRNA of clarithromycin resistant isolates was sequenced and transformed into sensitive H.
pylori strains. We clearly showed that other point mutations outside the 23S rRNA, or even
other mechanisms have to be responsible for the observed clarithromycin resistance pheno-
type. There are several conceivable mechanisms which have been described in other species,
such as efflux pumps [40], methylating enzymes [41], modulation of bacterial gene expression
[42], or other mechanisms. Further characterization of these patient isolates may lead to the
identification of novel, yet unknown mechanisms of clarithromycin resistance in African H.
pylori strains.
In total, there were very few differences in the microbiological characteristics of the 111
analyzed isolates. Almost 100% of the isolates were CagA-positive and were able to translocate
CagA. Considering vacA, all isolates were of the s1/m1 genotype.
Our results suggested an average pathology analyzed by gastroenterology reflected by two
gastric cancer cases and 15.5% ulcer cases of all 577 patients (independent of a proven H. pylori
infection). Earlier work suggested that H. pylori infection is associated with a 2-fold increased
risk of developing gastric cancer, with cumulative incidence rates of 1–2% [43], and a 4-fold
risk of developing ulcers (cumulative incidence rates 15–25%) [44]. The ulcer risk increases to
25-fold in cases where the H. pylori infection is located in the antrum [45]. Thus, compared to
published data, Nigerian patients of the current study exhibited an average disease outcome. It
should be noted that no ulcer was confirmed in histology. This is likely due to the fact that
ulcer edges are usually presented as granulated tissue, which may be an ulcer or can alterna-
tively indicate lesions in the mucosa. Discrepancies between gastroenterology and histology in
the identification of features such as ulcers and cancer have been previously reported [46].
Considering EPIYA regions of cagA, we discovered that the majority of patients had a
KDKGPE motif upstream of the EPIYA-A motif. This motif was previously observed in strains
of different origin [47], however no further experiments regarding its function were per-
formed. Whether this motif is unique to African strains and whether it may be linked to
pathology in Nigerian patients, has to be clarified in further studies. Likewise, the aforemen-
tioned gap in the ICEHptfs4b plasticity zone, which carries the duodenal ulcer promoting
(dupA) gene, might be an interesting basis for functional correlation studies. In conclusion,
our data support and extend the findings of previous studies and suggest that African strains
from our study cause a normal pathology, but are generally cagA- and vacA-positive.
In summary, we present the results of a cross-sectional study of H. pylori infection within
this patient cohort with a low infection rate. In addition, we found a uniformly high level of
resistance to metronidazole, which might partially be related to the clustering of sample loca-
tions, but may also relate to differences in health care practice in Nigeria resulting in an uncon-
trolled drug intake. Furthermore, we show a uniform presence of the major virulence factors
causing an average pathology.
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